WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 10/09/22

WuXi Biologics Co., Ltd. Removed from Unverified List PR Newswire WUXI, China , Oct. 9, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its s...

Summary The spotlight is on geopolitical risks for Chinese biologics outsourcing company WuXi Biologics, following the signing of a new Biden executive order in mid-September 2022. In late-September, WuXi Biologics announced that it intends to spend as much as $300 million buying ...

WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts PR Newswire WORCESTER, Mass. , Sept. 28, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Ma...

WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA PR Newswire WUXI, China , Sept. 19, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing ...

Wuxi Biologics ADR press release ( OTCPK:WXXWY ): 1H Non-GAAP EPS of RMB0.65. Revenue of RMB7.21B (+63.5% Y/Y). For further details see: Wuxi Biologics ADR Non-GAAP EPS of RMB0.65, revenue of RMB7.21B

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund (the “Fund”) declined 16.18% (Institutional Shares) during the second quart...

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Emerging Markets Fund (the “Fund”) declined 10.33% (Institutional Shares) during the second quarter o...

Drugs services provider WuXi Biologics has issued a positive earnings alert for the first half of the year, predicting revenue would rise by up to 63% and net profit would jump as much as 37%. The provider of outsourced pharmaceutical services has delivered on bullish market hopes of ...

WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore PR Newswire This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore , including a research and development service center and large-scale drug substance and dr...

Pfizer ( NYSE: PFE ) backed Chinese cancer drugmaker CStone Pharmaceuticals ( OTCPK:CSPHF ) is exploring strategic options, including a sale of the company, Bloomberg News reported citing people with knowledge of the matter. WuXi Healthcare Ventures, a unit of...